Hanmi Pharm, No.1 in Off-site Prescriptions for Four Consecutive First Halves

[Asia Economy Reporter Seo So-jeong] Hanmi Pharm has achieved the number one position in domestic outpatient prescription performance for the first half of the year for four consecutive years.

Hanmi Pharm (CEOs Woo Jong-su and Kwon Se-chang) announced on the 1st that, thanks to the growth of its self-developed improved and combination drugs such as the 'Amozantan' family, 'Rosuzet', and 'Hanmi Tams', it achieved outpatient prescription sales of 327.9 billion KRW in the first half of this year (based on Ubist data).

In particular, when including non-reimbursed sales such as the erectile dysfunction treatments 'Palpal' and 'Gugu', the outpatient prescription amount in the first half exceeds 364.4 billion KRW.

Hanmi Pharm stated, "More importantly, this is significant because it is 'product sales' achieved with domestically developed drugs using proprietary formulation technology, rather than 'merchandise sales' realized by importing drugs developed by foreign pharmaceutical companies."

According to Hanmi Pharm, among the top 10 most prescribed prescription drugs in Korea last year, the only products developed and commercialized independently by domestic pharmaceutical companies were Hanmi Pharm's Rosuzet and Amozantan.

Rosuzet, a treatment for dyslipidemia, has recorded the highest sales ever for a single combination drug product by a Korean pharmaceutical company, achieving sales of 53.4 billion KRW in the first half of this year, six years after its launch in 2015.

Woo Jong-su, CEO of Hanmi Pharm, said, "While the market share of imported drugs is increasing every year, Hanmi is leading the protection of Korea's pharmaceutical sovereignty based on its unique excellent formulation technology. We will focus our accumulated capabilities on developing global innovative new drugs and will surely realize the vision of becoming a pharmaceutical powerhouse."

This content was produced with the assistance of AI translation services.